Recombinant Human Tumor necrosis factor ligand superfamily member 11 (TNFSF11)

What is TNFSF11 and what are its primary functions in human biology?

TNFSF11, also known as RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand), is a protein coding gene that plays crucial roles in bone metabolism and immune system function. The protein functions primarily through cytokine activity and tumor necrosis factor receptor superfamily binding . TNFSF11 is essential in the signaling axis with RANK (Receptor Activator of Nuclear Factor-kappa B) and osteoprotegerin, which regulates bone remodeling and is implicated in various metabolic bone disorders .

The protein is particularly important during osteoclast differentiation, where it induces activation of CREB1 and mitochondrial ROS generation in a TMEM64 and ATP2A2-dependent manner, processes necessary for proper osteoclast generation .

What alternative names and identifiers are used for TNFSF11 in scientific literature?

Researchers should be aware of the multiple nomenclatures for TNFSF11 when conducting literature searches or database queries:

Additionally, TNFSF11 is identified by various database identifiers, including:

• HGNC: 11926

• NCBI Gene: 8600

• Ensembl: ENSG00000120659

• OMIM: 602642

• UniProtKB/Swiss-Prot: O14788

How is the TNFSF11 gene structured and regulated at the genomic level?

The TNFSF11 gene (NG_008990.1 RefSeq Gene) contains a promoter regulatory region that spans from -260 to +615 bp of the transcription start site (TSS) of isoform 1 . This promoter region contains CpG-rich sites that are subject to methylation regulation, which can influence gene expression.

The promoter CpG island at genomic position chr13:43148278-43149282 (GRCh37/hg19) shows a GC content of 66.9% and a ratio of observed to expected CpG of 0.74 . This region is evolutionarily conserved but contains fast-evolving sites with a mean phyloP100wayAll score of 0.253015, suggesting important functional roles that may vary across species .

What genetic polymorphisms in TNFSF11 are significant for researchers?

The rs1021188 single nucleotide polymorphism (SNP) located in the upstream region of the TNFSF11 gene has been associated with various bone disorders. Research has shown that this polymorphism may be gender-specific in its effects, with the CC genotype showing increased susceptibility to otosclerosis in men (p = 0.023) but not in women (p = 0.458) .

Twenty-six loci have been identified in linkage disequilibrium with rs1021188, with interesting population-specific patterns. European populations show patterns more similar to South Asians, while African populations demonstrate distinctive allele frequency patterns .

Notably, rs1021188 and rs2324851 show similar allele enrichment/depletion patterns across all populations, suggesting a potential interactive role between these two SNPs. The rs2324851 SNP has also been significantly associated with bone mineral density .

How does DNA methylation affect TNFSF11 expression?

DNA methylation of the TNFSF11 promoter region plays a significant role in regulating gene expression. Research has identified significant differences in DNA methylation status between disease states and healthy controls, with implications for gene regulation.

In otosclerosis patients, studies have shown:

• 4.53-fold decrease in global DNA methylation levels in female patients

• 4.83-fold decrease in global DNA methylation levels in male patients

These hypomethylation patterns could contribute to increased expression of TNFSF11 and subsequently to the development of disorders like otosclerosis. The methylation status can be measured using quantitative methylation-specific PCR (qMSP) with primers specific for methylated and unmethylated DNA .

Methodology for methylation analysis typically involves:

• Bisulfite conversion of DNA samples

• PCR amplification with methylation-specific primers

• Normalization with control genes (TSH2B for methylated DNA, GAPDH for unmethylated DNA)

• Quantification of methylation levels using standard models and ΔΔCq method

What bioinformatic approaches are useful for predicting functional effects of TNFSF11 variants?

Several bioinformatic tools and approaches can be employed to predict the functional effects of genetic variants in TNFSF11:

• RegulomeDB: This database can identify DNA features and regulatory elements in non-coding regions. The rs1021188 SNP has a RegulomeDB rank of 5, suggesting potential functions in transcription factor binding or DNase peak formation .

• HaploReg: This tool can annotate non-coding variants and predict effects on regulatory motifs. rs1021188 coincides with DNase sites and 11 altered motifs, including CEBPA, CEBPB, Dbx1, DIx3, DIx5, HNF1, Hoxb6, NKx2, Pou2f2, Prrx2, and p300 .

• RNAfold Web Server: This can predict RNA secondary structure changes. The rs1021188 SNP (C/T) shows local structure changes with different minimum free energies: -17.90 kcal/mol for rs1021188-C vs. -15.60 kcal/mol for rs1021188-T. Thermodynamic ensemble diversity also differs between variants (25.08 for C and 35.02 for T), suggesting potential effects on transcription .

• Phastcons and phyloP programs: These tools can assess evolutionary conservation of genomic regions, which may indicate functional importance .

What are the optimal methods for studying TNFSF11 promoter methylation?

When investigating TNFSF11 promoter methylation, researchers should consider these methodological approaches:

• Bisulfite Conversion: Treatment of DNA with bisulfite converts unmethylated cytosines to uracil while leaving methylated cytosines unchanged. This is a critical first step in methylation analysis.

• Methylation-Specific PCR (MSP): Use primers designed specifically for either methylated or unmethylated DNA after bisulfite conversion. For TNFSF11, primers targeting the promoter region spanning from -260 to +615 bp of the TSS have been successfully employed .

• Quantitative MSP (qMSP): This allows for quantification of methylation levels. Include appropriate controls:

  • Positive controls: Human bisulfite converted methylated and unmethylated DNA controls

  • Internal normalization: Human methylated DNA primer pair (TSH2B) for methylated DNA and Human unmethylated DNA primer pair (GAPDH) for unmethylated DNA

• Analysis Methods:

  • Standard models of comparative threshold cycles for quantification

  • ΔΔCq method for relative methylation levels between samples

  • Non-parametric statistical tests (e.g., Mann-Whitney) to determine significant differences

How should genotyping assays for TNFSF11 polymorphisms be designed?

For effective genotyping of TNFSF11 polymorphisms such as rs1021188, researchers should:

• Select appropriate genotyping method based on study requirements:

  • Direct sequencing for comprehensive analysis

  • PCR-RFLP (Restriction Fragment Length Polymorphism) for specific known variants

  • TaqMan assays for high-throughput screening

• Statistical analysis considerations:

  • Verify Hardy-Weinberg Equilibrium in control groups (significance level set at 0.001)

  • Use Chi-square test to compare genotypes between case and control groups

  • Employ Fisher's exact test for allelic model evaluation

  • Perform multivariate logistic regression to estimate associations between genotypes and other variables (e.g., gender)

• Population stratification analysis:

  • Consider gender-stratified analysis, as some TNFSF11 polymorphisms show gender-specific effects

  • Account for ethnicity, as different populations show distinct patterns of linkage disequilibrium

What protocols exist for producing functional recombinant human TNFSF11 for in vitro studies?

Production of functional recombinant human TNFSF11 requires careful consideration of expression systems and purification methods:

• Expression Systems:

  • Mammalian cell lines (e.g., HEK293, CHO) are often preferred for human proteins requiring post-translational modifications

  • E. coli systems may be used for protein fragments that don't require glycosylation

• Purification Strategy:

  • Affinity chromatography using tagged proteins (His-tag, GST-tag)

  • Size exclusion chromatography for higher purity

  • Ion exchange chromatography as needed

• Functionality Testing:

  • RANKL-RANK binding assays

  • Osteoclast differentiation assays

  • NF-κB activation assays

• Storage Considerations:

  • Optimal buffer conditions to maintain stability

  • Aliquoting to avoid freeze-thaw cycles

  • Temperature requirements (-80°C for long-term storage)

How can TNFSF11 signaling be studied in the context of bone disorders?

To investigate TNFSF11 signaling in bone disorders, researchers can employ multiple complementary approaches:

• In vitro osteoclast differentiation models:

  • Primary bone marrow-derived macrophages cultured with M-CSF and recombinant TNFSF11

  • RAW264.7 cell line stimulated with TNFSF11

  • Assessment of osteoclast formation through TRAP staining and counting multinucleated cells

• Signaling pathway analysis:

  • Western blotting for RANK pathway components (TRAF6, NF-κB, NFATC1)

  • Phosphorylation status of key signaling molecules

  • RNA-seq for transcriptional changes

  • Chromatin immunoprecipitation (ChIP) to identify transcription factor binding

• Genetic and epigenetic regulation:

  • Analysis of promoter methylation status using qMSP

  • Genotyping of key polymorphisms such as rs1021188

  • CRISPR-Cas9 genome editing to introduce or correct specific variants

• Functional assays:

  • Bone resorption assays on dentin or artificial bone substrates

  • Calcium flux measurements

  • Mitochondrial ROS generation assessment

What are the conflicting findings in TNFSF11 research and how might they be reconciled?

Several contradictions exist in TNFSF11 research literature that require careful consideration:

• Gender-specific effects: Some studies show gender-specific associations between TNFSF11 polymorphisms and disease outcomes. For example, the rs1021188 polymorphism has been associated with otosclerosis in men but not in women . These differences might be reconciled by:

  • Larger sample sizes with balanced gender representation

  • Investigation of hormonal influences on TNFSF11 expression

  • Analysis of gender-specific co-factors or modifiers

• Population differences: Research shows distinct patterns of linkage disequilibrium and allele frequencies across different ethnic populations . Reconciliation approaches include:

  • Population-specific studies

  • Meta-analyses with population stratification

  • Investigation of environmental or genetic background factors

• Methodological variations: Different methylation analysis techniques may yield varying results. Standardized approaches are needed:

  • Consensus on CpG regions to analyze

  • Standardized controls and normalization methods

  • Reporting of detailed methodological parameters

How can epigenetic regulation of TNFSF11 be comprehensively analyzed?

For comprehensive analysis of TNFSF11 epigenetic regulation, researchers should implement multi-layered approaches:

• DNA methylation analysis:

  • Bisulfite sequencing for base-resolution methylation mapping

  • Methylation array technologies for genome-wide screening

  • qMSP for targeted analysis of specific promoter regions

  • Single-cell methylation analysis for heterogeneity assessment

• Histone modification analysis:

  • ChIP-seq to identify histone modification patterns at the TNFSF11 locus

  • CUT&RUN for improved signal-to-noise ratio

  • Sequential ChIP to identify co-occurring modifications

• Chromatin accessibility:

  • ATAC-seq to identify open chromatin regions

  • DNase-seq to identify DNase hypersensitivity sites

  • Analysis of chromatin conformation using 3C, 4C, or Hi-C technologies

• Integration with functional data:

  • Correlation of epigenetic patterns with gene expression data

  • Epigenetic editing using CRISPR-dCas9 systems to establish causality

  • Multi-omics data integration for comprehensive regulatory landscape

How does TNFSF11 expression contribute to different pathological conditions?

TNFSF11 dysregulation has been implicated in various pathological conditions beyond bone disorders:

• Bone disorders:

  • Osteoporosis: Increased TNFSF11 levels lead to excessive bone resorption

  • Osteopetrosis: TNFSF11 deficiency results in impaired osteoclast formation

  • Otosclerosis: Altered TNFSF11 expression affects bone remodeling in the otic capsule

• Immune disorders:

  • Rheumatoid arthritis: Elevated TNFSF11 contributes to bone erosion

  • Periodontal disease: TNFSF11 mediates alveolar bone loss

• Malignancies:

  • Bone metastases: Tumor-derived TNFSF11 promotes osteolytic lesions

  • Multiple myeloma: TNFSF11 contributes to myeloma bone disease

Research methodologies to study these connections include:

• Animal models of specific diseases

• Analysis of patient samples for TNFSF11 expression and polymorphisms

• In vitro disease models with manipulation of TNFSF11 levels

What are the current challenges in translating TNFSF11 research findings to clinical applications?

Researchers face several challenges when translating TNFSF11 findings to clinical applications:

• Target specificity:

  • TNFSF11 plays physiological roles in multiple systems

  • Tissue-specific targeting remains challenging

  • Differentiating pathological from physiological functions

• Biomarker validation:

  • Standardization of TNFSF11 measurement methods

  • Establishing clinically relevant thresholds

  • Accounting for confounding factors (age, gender, comorbidities)

• Genetic heterogeneity:

  • Population-specific polymorphism effects

  • Complex interactions with other genetic factors

  • Epigenetic influences on gene expression

• Methodological considerations:

  • Reproducibility of epigenetic findings across different techniques

  • Integration of multi-omics data

  • Translation between in vitro and in vivo findings